Dan Salvo, Author at Forge Biologics

Forge Biologics Announces Closing of $120 Million Series B FinancingPosted on April 29, 2021 (April 29, 2021) by Dan SalvoinBiologics News&Press Releases
Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing SummitPosted on April 22, 2021 (June 15, 2021) by Dan SalvoinBiologics News&Press Releases
Forge Biologics to Present at 2021 Virtual Cell and Gene Meeting on the MediterraneanPosted on April 6, 2021 (June 15, 2021) by Dan SalvoinBiologics News&Press Releases
FDA Fast Track, ODD, and RPDD Designations for FBX-101 Gene Therapy for Patients with Krabbe DiseasePosted on February 16, 2021 (April 29, 2021) by Dan SalvoinBiologics News&Press Releases
United Leukodystrophy FoundationPosted on January 27, 2021 (April 29, 2021) by Dan SalvoinBiologics News
VIDEO: Manufacturing CapabilitiesPosted on January 25, 2021 (April 29, 2021) by Dan SalvoinBiologics News
“Building Better” Blog: Forge Biologics SpotlightPosted on January 22, 2021 (April 29, 2021) by Dan SalvoinBiologics News
RESKUE Trial for Patients with Krabbe DiseasePosted on January 21, 2021 (April 29, 2021) by Dan SalvoinBiologics News
Announcing: Blaze Vector™ ProductionPosted on January 12, 2021 (April 29, 2021) by Dan SalvoinBiologics News